"How is it going to help?": Exploring Black breast cancer patients' questions about biomarker testing to predict chemotherapy-induced peripheral neuropathy.

Autor:	Head KJ; Department of Communication Studies, 425 University Blvd, Indiana University-Purdue University Indianapolis, IN, 46202, United States., Hayes LR; Pink-4-Ever Ending Disparities, 8770 Commerce Park Place F, Indianapolis, IN 46286, United States., Miller NE; Pink-4-Ever Ending Disparities, 8770 Commerce Park Place F, Indianapolis, IN 46286, United States., Shakil S; Department of Biomedical Engineering, 425 University Blvd, Indiana University-Purdue University Indianapolis, IN 46202, United States., Bales CL; Department of Medicine-Division of Clinical Pharmacology, 950 West Walnut Street, Rm 402 Research Institute II (R2), Indianapolis, IN 46202, United States., Schneider BP; Department of Medicine-Division of Hematology/Oncology, Indiana Cancer Pavilion, 535 Barnhill Drive - 473, Indianapolis, IN 46202, United States.
Jazyk:	angličtina
Zdroj:	PEC innovation [PEC Innov] 2022 Dec 13; Vol. 2, pp. 100118. Date of Electronic Publication: 2022 Dec 13 (Print Publication: 2023).
DOI:	10.1016/j.pecinn.2022.100118
Abstrakt:	Objective: Many Black breast cancer patients experience chemotherapy-induced peripheral neuropathy (CIPN). Our study assessed Black breast cancer patients' questions about a biomarker test that can predict likelihood of CIPN. Methods: Nineteen Black women who were previous/current breast cancer patients participated in focus groups. Researchers briefly explained CIPN and the biomarker test, and then participants were asked what questions they would have about the test and its use in treatment decisions. These participant-voiced questions composed the data for this study and were analyzed using thematic analysis. Results: Participants' questions centered on six themes: reasons for the test, effect on timeline of breast cancer treatment, testing procedure, limits of test (including accuracy), research done to develop this test (including research participants), and concerns about personal information connected to the test (including DNA). Conclusion: This study provides an exploratory look at questions that Black breast cancer patients may have about toxicity biomarker testing use in breast cancer treatment decisions. Innovation: These findings provide a starting point for developing patient-centered approaches for integrating this precision medicine tool into clinical care. The methodological choice to generate participants' questions (rather than answers to a question) led to robust, actionable data. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors reports financial support was provided by Susan G Komen Breast Cancer Foundation. All authors reports financial support was provided by Genentech Inc. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu